Daratumumab can also bind to CD38 present on red blood cells and interfere with routine testing for clinically significant antibodies. People will show a panreactive antibody panel, including a positive auto-control, which tends to mask the presence of any clinically significant antibodies. Treatment of the antibody panel cells with dithiothreitol (DTT) and repeating testing will effectively negate the binding of daratumumab to CD38 on the red blood cell surface; however, DTT also i… WebJan 27, 2024 · Treatment of multiple myeloma patients with daratumumab, a novel anti‐CD38 MoAb, resulted in false‐positive indirect antiglobulin tests (IATs) for all patients for 2 to 6 months after infusion, which precluded the correct identification of irregular blood group antibodies for patients requiring blood transfusion. 124
Diagnosis of antiphospholipid syndrome - UpToDate
WebNational Center for Biotechnology Information WebAn anti-CD38 antibody, daratumumab, has been recently approved for multiple myeloma patients who are refractory to conventional therapy. The CD38 antigen is present on red … cirsium propco limited companies house
Overcoming the Interference of Daratumumab with …
WebSep 18, 2024 · Positive results from the IAT were observed during routine blood screening in patients treated with daratumumab. Daratumumab was subsequently found to interfere with blood bank compatibility tests, including antibody screening and full crossmatching (both by IAT) that may be part of a pretransfusion assessment. WebJul 11, 2024 · Daratumumab is a monoclonal antibody used as monotherapy or in combination with other treatments to treat multiple myeloma. The agent is targeted to CD-38, which is also expressed on … WebAbstract: Daratumumab, a monoclonal antibody therapeutic, is highly efficacious and widely used in all stages of multiple myeloma and amyloidosis and has promising activity … diamond painting race auto